You are here: Industry Insights > Dermira

News List

Lilly to acquire Dermira for approximately $1.1bn pharmaceutical-technology
January 14, 2020
Eli Lilly and Company (Lilly) has signed a definitive agreement to acquire biopharmaceutical firm Dermira for approximately $1.1bn in cash. As agreed, Lilly will acquire all outstanding shares of Dermira for $18.75 per share.
Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis biospectrumasia
October 24, 2018
Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
No sweat? Dermira snags reps, sets price and plots branded ads for Qbrexza launch fiercepharma
September 06, 2018
Dermira's currently running unbranded advertising to raise awareness about hyperhidrosis, or excessive sweating, will run concurrently with branded ads in the works.
Dermira Receives FDA Approval for Qbrexza americanpharmaceuticalreview
July 11, 2018
Dermira announced the U.S. Food and Drug Administration (FDA) has approved Qbrexza (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.
Dermira’s Acne Medication Olumacostat Glaseretil Tanks in Two Phase III Trials biospace
March 06, 2018
Going into Phase III trials, Menlo Park, California-based Dermira, Inc. and numerous investors were optimistic about the company’s olumacostat glasaretil for acne.